These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10562327)

  • 1. Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy.
    Mittler RS; Bailey TS; Klussman K; Trailsmith MD; Hoffmann MK
    J Exp Med; 1999 Nov; 190(10):1535-40. PubMed ID: 10562327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-1BB: still in the midst of darkness.
    Kwon B; Moon CH; Kang S; Seo SK; Kwon BS
    Mol Cells; 2000 Apr; 10(2):119-26. PubMed ID: 10850651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel adenovirus expressing human 4-1BB ligand enhances antitumor immunity.
    Yoshida H; Katayose Y; Unno M; Suzuki M; Kodama H; Takemura S; Asano R; Hayashi H; Yamamoto K; Matsuno S; Kudo T
    Cancer Immunol Immunother; 2003 Feb; 52(2):97-106. PubMed ID: 12594573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marked expansion of CD11c+CD8+ T-cells in melanoma-bearing mice induced by anti-4-1BB monoclonal antibody.
    Ju SA; Park SM; Lee SC; Kwon BS; Kim BS
    Mol Cells; 2007 Aug; 24(1):132-8. PubMed ID: 17846508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment with anti-HER2/neu and anti-4-1BB monoclonal antibodies induces a synergistic antitumor effect but requires dose optimization to maintain immune memory for protection from lethal rechallenge.
    Kim HY; Choi JH; Haque MM; Park JH; Kim IH; Choi BK; Lee A; Park S
    Cancer Immunol Immunother; 2022 Apr; 71(4):967-978. PubMed ID: 34988585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZH2 Inhibition Compromises α4-1BB-Mediated Antitumor Efficacy by Reducing the Survival and Effector Programming of CD8
    Stairiker CJ; Pfister SX; Hendrickson E; Yang W; Xie T; Lee C; Zhang H; Dillon C; Thomas GD; Salek-Ardakani S
    Front Immunol; 2021; 12():770080. PubMed ID: 34925340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effector CD8 T cells possess suppressor function after 4-1BB and Toll-like receptor triggering.
    Myers L; Takahashi C; Mittler RS; Rossi RJ; Vella AT
    Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5348-53. PubMed ID: 12695569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of mouse 4-1BB expression: multiple promoter usages and a splice variant.
    Kim JD; Kim CH; Kwon BS
    Mol Cells; 2011 Feb; 31(2):141-9. PubMed ID: 21347708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites.
    Martin AL; Powell C; Nagy MZ; Innamarato P; Powers J; Nichols D; Anadon CM; Chaurio RA; Kim S; Wang MH; Gong B; Wang X; Scheutz TJ; Antonia SJ; Conejo-Garcia JR; Perez BA
    Cancer Immunol Immunother; 2023 Jun; 72(6):1445-1460. PubMed ID: 36469096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1.
    Enell Smith K; Fritzell S; Nilsson A; Barchan K; Rosén A; Schultz L; Varas L; Säll A; Rose N; Håkansson M; von Schantz L; Ellmark P
    Cancer Immunol Immunother; 2023 Dec; 72(12):4145-4159. PubMed ID: 37796298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity.
    Fisher TS; Kamperschroer C; Oliphant T; Love VA; Lira PD; Doyonnas R; Bergqvist S; Baxi SM; Rohner A; Shen AC; Huang C; Sokolowski SA; Sharp LL
    Cancer Immunol Immunother; 2012 Oct; 61(10):1721-33. PubMed ID: 22406983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-1BB immunotherapy: advances and hurdles.
    Singh R; Kim YH; Lee SJ; Eom HS; Choi BK
    Exp Mol Med; 2024 Feb; 56(1):32-39. PubMed ID: 38172595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.
    White AL; Chan HT; French RR; Willoughby J; Mockridge CI; Roghanian A; Penfold CA; Booth SG; Dodhy A; Polak ME; Potter EA; Ardern-Jones MR; Verbeek JS; Johnson PW; Al-Shamkhani A; Cragg MS; Beers SA; Glennie MJ
    Cancer Cell; 2015 Jan; 27(1):138-48. PubMed ID: 25500122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of The Effect of Metal-based Medicine Arsenicum album on Humoral Immune Response in SRBC-immunized Mice.
    Behera S; Sharma M; Lal R; Regar RK; Tripathi D; Gupta P; Kumar GVN; Verma D; Kaushik S; Khurana A
    Endocr Metab Immune Disord Drug Targets; 2024 Jan; ():. PubMed ID: 38192149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetically mannosylated antigens induce antigen-specific humoral tolerance and reduce anti-drug antibody responses to immunogenic biologics.
    Wallace RP; Refvik KC; Antane JT; Brünggel K; Tremain AC; Raczy MR; Alpar AT; Nguyen M; Solanki A; Slezak AJ; Watkins EA; Lauterbach AL; Cao S; Wilson DS; Hubbell JA
    Cell Rep Med; 2024 Jan; 5(1):101345. PubMed ID: 38128533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
    Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB
    Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors.
    Melero I; Shuford WW; Newby SA; Aruffo A; Ledbetter JA; Hellström KE; Mittler RS; Chen L
    Nat Med; 1997 Jun; 3(6):682-5. PubMed ID: 9176498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.
    Ascierto PA; Simeone E; Sznol M; Fu YX; Melero I
    Semin Oncol; 2010 Oct; 37(5):508-16. PubMed ID: 21074066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses.
    Shuford WW; Klussman K; Tritchler DD; Loo DT; Chalupny J; Siadak AW; Brown TJ; Emswiler J; Raecho H; Larsen CP; Pearson TC; Ledbetter JA; Aruffo A; Mittler RS
    J Exp Med; 1997 Jul; 186(1):47-55. PubMed ID: 9206996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy of cancer with 4-1BB.
    Vinay DS; Kwon BS
    Mol Cancer Ther; 2012 May; 11(5):1062-70. PubMed ID: 22532596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.